Axil Capital is a venture capital and private equity firm investing in early-stage biomedical & healthcare technology companies that is headquartered in Tokyo, Japan and was founded in 2017 by Fred Shane and Hiroshi Gonaikawa. Axil Capital was spun out of Mizuho Securities in 2017 after receiving investment from the Japanese Government, a global pharmaceutical company, and a few small investors.
Notable investments made by Axil Capital include: Jolly Good! (sereis B-II), Frequency Therapeutics (series B and series C), United Immunity (series A), TechsoMed (series A).
According to the firms website (as of November 2019), Axil Capital has one investment fund called the Axil Life Science & Healthcare Fund No.1 L.P. (ALHF I).